Improvement of oligonucleotide manufacturing processes can focus on numerous areas; including yield, purity, scale-up conditions amongst others. This webinar intends to discuss innovations in oligonucleotide manufacturing with a focus on Cost of Goods (COGS) reduction. Lower oligonucleotides COGS would allow to develop oligonucleotide therapeutics for disease areas that can’t afford today’s cost. Today oligonucleotide drugs are too expensive to compete with, e.g. small molecule drugs.
Which manufacturing innovations were developed in the last few years and what additional improvements to expect in the near future?